# Second-line Chemotherapy in Castration Resistant Prostate Cancer

> **NCT01558219** · PHASE2 · COMPLETED · sponsor: **Tampere University Hospital** · enrollment: 60 (actual)

## Conditions studied

- Metastatic Prostate Cancer

## Interventions

- **DRUG:** cabacitaxel

## Key facts

- **NCT ID:** NCT01558219
- **Lead sponsor:** Tampere University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2016-10-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01558219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01558219, "Second-line Chemotherapy in Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01558219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*